ANNUAL GENERAL MEETING OF Q-MED AB (publ)

ANNUAL GENERAL MEETING OF Q-MED AB (publ)

The Annual General Meeting of Q-Med AB (publ) was held on May 3, 2007 at 3 p.m.
on Q-Med's new premises, which are entered from Fyrisvallsgatan 5, Uppsala.

Dividend
The meeting decided that a dividend of 2 SEK per share shall be paid to
shareholders.

Board and fees
The meeting decided to re-elect the following members of the Board, Håkan
Edström, Bertil Hult, Anders Milton, Pia Rudengren, Åsa Rödén, Pernilla Ström
och Bengt Ågerup for the period up until the end of the next Annual General
Meeting.

The meeting also re-elected Pia Rudengren as the Chair of the Board.

The meeting also decided that Board fees of 1,050,000 SEK in total be paid for
the period 2007/2008, with 300,000 SEK to the Chair of the Board and 150,000 SEK
to each of the other members of the Board, except for Bengt Ågerup, who is an
employee of the company and shall therefore not receive a Board fee, which means
unchanged fees compared with the previous year.

Auditors' fees shall be paid in accordance with reasonable invoicing.

A fee of 180,000 SEK in total shall be paid for work on the audit committee, to
be divided among the three members as follows: 90,000 SEK to the Chair of the
committee and 45,000 SEK to each of the other two committee members.

Election committee
The Annual General Meeting decided that the election committee shall continue to
consist of three members and re-elected Robert Wikholm as Chair with the
assignment of finding, at the latest during the third quarter, two
representatives from the major owners to be included in the election committee,
and that a fee of SEK 60,000 be paid to the election committee, to be allocated
in accordance with the decision of the election committee. This is an unchanged
fee compared with the previous year. 

Principles for remuneration
Finally, the meeting decided on principles for remuneration and other conditions
of employment for senior management in accordance with the proposal of the
Board.

Queries should be addressed to: 
Madelene Sandgren, Director Investor Relations and Corporate Communications
Tel: 070-974 90 15


Q-Med AB is a rapidly growing and profitable biotechnology/medical device
company. The company develops, manufactures, markets and sells primarily medical
implants. The majority of the products are based on the company's patented
technology, NASHA™ for the production of stabilized non-animal hyaluronic acid. 
The product portfolio today contains: RESTYLANE for the filling out of lips and
facial wrinkles and for facial contouring, DUROLANE, for the treatment of
osteoarthritis of the hip and knee joints, DEFLUX for the treatment of
vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children,
ZUIDEX, for the treatment of stress urinary incontinence in women and SOLESTA,
for the treatment of fecal incontinence. Sales are made through the company's
own subsidiaries or distributors in over 70 countries. Q-Med today has just over
600 co-workers, with approximately 400 at the company's head office and
production facility in Uppsala, Sweden. Q-Med AB is listed in the Large Cap
segment of the OMX Nordic Stock Exchange in Stockholm.

NASHA, DUROLANE, SOLESTA, ZUIDEX, IMPLACER, DEFLUX and all product names within
the RESTYLANE family are trademarks that belong to Q-Med AB.